EDP-514 is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase I program in Hepatitis B. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of EDP-514’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for EDP-514 is expected to reach an annual total of $79 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EDP-514 is under development for the treatment of hepatitis B. It acts by targeting hepatitis B virus core antigen (HBcAg). It is administered through oral route and formulated as capsule.
Enanta Pharmaceuticals Overview
Enanta Pharmaceuticals (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Enanta also develops EDP-938, a potent N-protein inhibitor for the respiratory syncytial virus; and programs to discover and develop chemical entities for the treatment of the hepatitis B virus. The company also develops and markets protease inhibitor compounds for the treatment of the hepatitis C virus through collaborative development and license agreement with AbbVie. Enanta is headquartered in Watertown, Massachusetts, the US
The company reported revenues of (US Dollars) US$86.2 million for the fiscal year ended September 2022 (FY2022), a decrease of 11.2% over FY2021. The operating loss of the company was US$123.8 million in FY2022, compared to an operating loss of US$109.6 million in FY2021. The net loss of the company was US$121.8 million in FY2022, compared to a net loss of US$79 million in FY2021. The company reported revenues of US$23.6 million for the first quarter ended December 2022, an increase of 16.1% over the previous quarter.
For a complete picture of EDP-514’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.